Vanda Pharmaceuticals (VNDA) Q4 2025 earnings summary

Executive summary

• Achieved 9% year-over-year revenue growth in 2025 to $216.1 million, driven by Fanapt's 24% sales increase and significant prescription gains.

• Advanced regulatory and clinical milestones, including FDA approval of Nereus for motion sickness and submission of Bysanti and imsidolimab applications.

• Expanded commercial infrastructure, doubling Fanapt sales force and launching direct-to-consumer campaigns, supporting continued growth.

• Significant commercial momentum for Fanapt, with total prescriptions up 28% and new-to-brand prescriptions up 149% year-over-year.

• 2026 revenue guidance for marketed products is $230–$260 million, with Fanapt expected to contribute $150–$170 million.

Financial highlights

• Full-year 2025 revenues reached $216.1 million, up from $198.8 million in 2024; Q4 2025 revenues were $57.2 million, up 8% year-over-year.

• Fanapt net sales rose 24% to $117.3 million; Hetlioz sales declined 7% to $71.4 million; Ponvory sales were $27.4 million, down 2%.

• Net loss for 2025 was $220.5 million, including a one-time, non-cash tax charge of $113.7 million; non-GAAP net loss was $106.8 million.

• Operating expenses increased to $367.3 million in 2025, up from $239.4 million in 2024.

• Cash and equivalents at year-end were $263.8 million, down $110.8 million from prior year.

Outlook and guidance

• 2026 revenue guidance for Fanapt, Hetlioz, and Ponvory is $230–$260 million, implying 13% growth at midpoint.

• Fanapt sales expected between $150–$170 million, driven by prescription volume growth.

• Additional revenue growth anticipated from Nereus launch and potential approvals of Bysanti and imsidolimab.

• Hetlioz sales projected to decline further; Ponvory to see modest growth.

• No 2026 cash guidance; cash burn expected to increase due to milestone payments and commercial investments.